Filtered By:
Condition: Atrial Fibrillation
Drug: Coumadin

This page shows you your search results in order of relevance. This is page number 19.

Order by Relevance | Date

Total 2924 results found since Jan 2013.

Efficacy and safety of dabigatran, rivaroxaban, and warfarin for stroke prevention in Chinese patients with atrial fibrillation: the Hong Kong Atrial Fibrillation Project
ConclusionsIn Chinese AF patients, the benefits of warfarin therapy for stroke prevention and ICH reduction depend on TTR. Of the treatments compared, dabigatran, as well as rivaroxaban 20 mg daily, was associated with lowest ischemic stroke and ICH rates.
Source: Clinical Cardiology - September 30, 2016 Category: Cardiology Authors: Wen ‐Hua Li, Duo Huang, Chern‐En Chiang, Chu‐Pak Lau, Hung‐Fat Tse, Esther W. Chan, Ian C.K. Wong, Gregory Y. H. Lip, Pak‐Hei Chan, Chung‐Wah Siu Tags: Clinical Investigations Source Type: research

Anemia Is Associated With Bleeding and Mortality, but Not Stroke, in Patients With Atrial Fibrillation: Insights From the ARISTOTLE Trial
Conclusions Chronic anemia is associated with a higher incidence of bleeding complications and mortality, but not of stroke, in anticoagulated patients with AF. Apixaban is an attractive anticoagulant for stroke prevention in patients with AF with or without anemia.
Source: American Heart Journal - December 21, 2016 Category: Cardiology Source Type: research

Ischaemic and haemorrhagic stroke associated with non-vitamin K antagonist oral anticoagulants and warfarin use in patients with atrial fibrillation: a nationwide cohort study
Conclusions</div>Among anticoagulant-naïve AF patients, treatment with NOACs was not associated with significantly lower risk of stroke/TE compared with VKA, but intracranial bleeding risk was significantly lower with dabigatran and apixaban.</span>
Source: European Heart Journal - October 14, 2016 Category: Cardiology Source Type: research

Factors Associated with Non-vitamin K Antagonist Oral Anticoagulants for Stroke Prevention in Patients with New-Onset Atrial Fibrillation: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II)
Conclusions In contemporary clinical practice up to three-fourths of patients with new-onset AF are now initially treated with a NOAC for stroke prevention. Those selected for NOAC treatment had lower stroke and bleeding risk profiles, were more likely treated by cardiologists and had higher socioeconomic status. Trial Registration clinicaltrials.gov Identifier: NCT01701817
Source: American Heart Journal - April 4, 2017 Category: Cardiology Source Type: research

Persistence of secondary prevention medication and related factors for acute ischemic stroke and transient ischemic attack in China.
CONCLUSIONS: More than half of patients with AIS and TIA reported discontinuing one or more secondary prevention medications within 3 months of hospital discharge. Several factors associated with medication persistence were identified. Here, we propose strategies that could be implemented to improve the quality of secondary prevention. PMID: 28420316 [PubMed - as supplied by publisher]
Source: Neurological Research - April 21, 2017 Category: Neurology Tags: Neurol Res Source Type: research

Is von Willebrand factor associated with stroke and death at mid-term in patients with non-valvular atrial fibrillation?
CONCLUSIONS: High vWF plasma concentrations may discriminate patients with NVAF at greater risk of stroke or all-cause death. PMID: 29685722 [PubMed - as supplied by publisher]
Source: Archives of Cardiovascular Diseases - April 20, 2018 Category: Cardiology Authors: Ancedy Y, Berthelot E, Lang S, Ederhy S, Boyer-Chatenet L, Di Angelantonio E, Soulat-Dufour L, Etienney A, Adavane-Scheublé S, Boccara F, Cohen A Tags: Arch Cardiovasc Dis Source Type: research

Cost-Effectiveness of Left Atrial Appendage Closure With the WATCHMAN Device Compared With Warfarin or Non-Vitamin K Antagonist Oral Anticoagulants for Secondary Prevention in Nonvalvular Atrial Fibrillation Clinical Sciences
Conclusions—Upfront procedure costs initially make LAAC higher cost than warfarin and the non–vitamin K antagonist oral anticoagulants, but within 10 years, LAAC delivers more quality-adjusted life years and has lower total costs, making LAAC the most cost-effective treatment strategy for secondary prevention of stroke in atrial fibrillation.
Source: Stroke - May 25, 2018 Category: Neurology Authors: Vivek Y. Reddy, Ronald L. Akehurst, Stacey L. Amorosi, Meghan B. Gavaghan, Deanna S. Hertz, David R. Holmes Jr Tags: Atrial Fibrillation, Cost-Effectiveness Original Contributions Source Type: research

Comparison of Stroke- and Bleed-related Healthcare Resource Utilization and Costs among Patients with Newly Diagnosed Non-Valvular Atrial Fibrillation and Newly Treated with Dabigatran, Rivaroxaban, or Warfarin.
CONCLUSIONS: The results suggest that dabigatran patients had lower bleed-related HCRU and lower bleed-related PPPM costs than rivaroxaban patients, and lower outpatient stroke-related HCRU, higher bleed-related outpatient HCRU, and lower bleed-related PPPM costs than warfarin patients. It provides valuable stroke-related and bleed-related HCRU and costs information among commercially-insured and Medicare patients. PMID: 30251553 [PubMed - as supplied by publisher]
Source: Expert Review of Pharmacoeconomics and Outcomes Research - September 27, 2018 Category: Health Management Tags: Expert Rev Pharmacoecon Outcomes Res Source Type: research

Temporary oral anticoagulation after MitraClip - a strategy to lower the incidence of post-procedural stroke?
CONCLUSIONS: Temporary oral anticoagulation might be a strategy to reduce the incidence of stroke within the first 30 days after the MitraClip procedure. Bleeding events were not significantly altered due to temporary oral anticoagulation. PMID: 30650019 [PubMed - as supplied by publisher]
Source: Acta Cardiologica - January 18, 2019 Category: Cardiology Tags: Acta Cardiol Source Type: research

Effect of Warfarin on Ischemic Stroke, Bleeding, and Mortality in Patients with Atrial Fibrillation Receiving Peritoneal Dialysis
ConclusionThere is no significant association between warfarin treatment with risks of mortality, ischemic stroke or bleeding in patients with atrial fibrillation receiving peritoneal dialysis.
Source: American Journal of Cardiovascular Drugs - April 22, 2019 Category: Cardiology Source Type: research

Augmented Intelligence Decision Tool for Stroke Prediction Combines Factors from CHA2DS2 ‐VASc and the Intermountain Risk Score for Patients with Atrial Fibrillation
ConclusionsA temporally dynamic risk score, IMRS ‐VASc was derived and validated as a predictor of stroke in AF outpatients. IMRS‐VASc requires further validation and the evaluation of its use in guiding care and treatment decisions for AF patients.This article is protected by copyright. All rights reserved.
Source: Journal of Cardiovascular Electrophysiology - May 21, 2019 Category: Cardiology Authors: Benjamin D. Horne, Victoria Jacobs, Heidi T. May, Kevin G. Graves, T. Jared Bunch Tags: ORIGINAL ‐ CLINICAL Source Type: research

Adherence to Anticoagulation and Risk of Stroke Among Medicare Beneficiaries Newly Diagnosed with Atrial Fibrillation
The objective of this study was to compare the risk of stroke in atrial fibrillation (AF) with adherent use of oral anticoagulation (OAC), non-adherent use, and non-use of OAC.MethodsUsing 2013 –2016 Medicare claims data, we identified patients newly diagnosed with AF in 2014–2015 and collected prescriptions filled for OAC in the 12 months after AF diagnosis (n = 39,272). We categorized participants each day into three time-dependent exposures: adherent use (≥ 80% of the previous 30 days covered with OAC), non-adherent use (0–80% covered with OAC), and non-use (0%). We constructed Cox proportional hazards m...
Source: American Journal of Cardiovascular Drugs - September 15, 2019 Category: Cardiology Source Type: research

Structural heart intervention for prevention of embolic and hemorrhagic stroke: The new field of neurocardiology.
Abstract Cardiogenic stroke (CS), characteristic causes of which include atrial fibrillation (AF) and right-to-left shunting due to a patent foramen ovale (PFO), has a well-known tendency to be associated with a more extensive ischemic area. This may result in severe neurological damage, and require strict life-long antithrombotic therapy. However, the fact that some patients have problems complying with the requirement for extended oral antithrombotic treatment has motivated the development of alternative approaches for stroke prevention. Heart structures such as the left atrial appendage (LAA) and PFO are potent...
Source: Journal of Cardiology - May 28, 2020 Category: Cardiology Authors: Morino Y, Nakajima Y Tags: J Cardiol Source Type: research

Antiplatelet Agents and Oral Anticoagulant Use in Patients with Atrial Fibrillation and Carotid Artery Disease After First-Time Ischaemic Stroke
CONCLUSIONS: The results suggest for patients with AF and carotid artery disease after ischaemic stroke, receiving NOACs without APA is associated with a lower risk of major bleeding with no negative impact on recurrent stroke or mortality. Evidence from randomised trials is needed to confirm this finding.PMID:36692658 | DOI:10.1007/s10557-023-07433-4
Source: Atherosclerosis - January 24, 2023 Category: Cardiology Authors: Stephanie L Harrison Benjamin J R Buckley Deirdre A Lane Elnara Fazio-Eynullayeva Paula Underhill Andrew Hill David J Werring Gregory Y H Lip Source Type: research